Matthew D Ringel

Summary

Country: USA

Publications

  1. ncbi Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy
    Alan R Burningham
    Department of Otolaryngology Head and Neck Surgery, Georgetown University Hospital, Washington, DC 20007, USA
    Otolaryngol Head Neck Surg 132:840-4. 2005
  2. ncbi Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells
    Matthew D Ringel
    Department of Medicine, Washington Hospital Center and MedStar Research Institute, Washington, D C 20010, USA
    J Clin Endocrinol Metab 87:2399. 2002
  3. ncbi Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells
    Eri Miyagi
    Section of Endocrinology and Laboratory of Molecular Endocrinology, Washington Hospital Center MedStar Research Institute, Washington, DC, USA
    Mol Carcinog 41:98-107. 2004
  4. ncbi 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels
    Milena Braga-Basaria
    Section of Endocrinology, Washington Hospital Center MedStar Research Institute, Washington, DC 20010, USA
    J Clin Endocrinol Metab 89:2982-8. 2004
  5. ncbi Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction
    Victor J Bernet
    Endocrine, Diabetes, and Metabolism Service, Walter Reed Army Medical Center, Washington, D C 20307, USA
    J Clin Endocrinol Metab 87:4792-6. 2002
  6. ncbi Akt: a potential target for thyroid cancer therapy
    Faiza Kada
    The Washington Hospital Center MedStar Research Institute, Washington, DC, USA
    Curr Drug Targets Immune Endocr Metabol Disord 4:181-5. 2004
  7. pmc Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion
    Vasily Vasko
    Department of Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 104:2803-8. 2007
  8. ncbi Akt controls vascular smooth muscle cell proliferation in vitro and in vivo by delaying G1/S exit
    Eugenio Stabile
    Cardiovascular Research Institute, Washington Hospital Center, 110 Irving St NW, 4B 1, Washington, DC 20010, USA
    Circ Res 93:1059-65. 2003
  9. ncbi Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice
    Andrew J Bauer
    Department of Pediatrics, Walter Reed Army Medical Center, Washington, DC, USA
    Thyroid 12:953-61. 2002
  10. ncbi Epidermal growth factor inhibition of c-Myc-mediated apoptosis through Akt and Erk involves Bcl-xL upregulation in mammary epithelial cells
    Danica Ramljak
    Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20057, USA
    Exp Cell Res 287:397-410. 2003

Collaborators

Detail Information

Publications28

  1. ncbi Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy
    Alan R Burningham
    Department of Otolaryngology Head and Neck Surgery, Georgetown University Hospital, Washington, DC 20007, USA
    Otolaryngol Head Neck Surg 132:840-4. 2005
    ..The purpose of this study is to compare the presentation and short-term response to therapy of these variants and to determine if FVPTC is a more aggressive form of thyroid cancer that warrants intensive therapy...
  2. ncbi Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells
    Matthew D Ringel
    Department of Medicine, Washington Hospital Center and MedStar Research Institute, Washington, D C 20010, USA
    J Clin Endocrinol Metab 87:2399. 2002
    ..Taken together, these data suggest a potential role for metastin and/or metastin receptors in modulating the biological behavior of thyroid cancers...
  3. ncbi Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells
    Eri Miyagi
    Section of Endocrinology and Laboratory of Molecular Endocrinology, Washington Hospital Center MedStar Research Institute, Washington, DC, USA
    Mol Carcinog 41:98-107. 2004
    ....
  4. ncbi 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels
    Milena Braga-Basaria
    Section of Endocrinology, Washington Hospital Center MedStar Research Institute, Washington, DC 20010, USA
    J Clin Endocrinol Metab 89:2982-8. 2004
    ..These data suggest that sensitivity of thyroid cancer cells to 17-AAG-induced cytotoxicity relates to Hsp90 levels rather than histological subtype and that thyroid cancer cells have a reduced apoptotic response to 17-AAG...
  5. ncbi Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction
    Victor J Bernet
    Endocrine, Diabetes, and Metabolism Service, Walter Reed Army Medical Center, Washington, D C 20307, USA
    J Clin Endocrinol Metab 87:4792-6. 2002
    ....
  6. ncbi Akt: a potential target for thyroid cancer therapy
    Faiza Kada
    The Washington Hospital Center MedStar Research Institute, Washington, DC, USA
    Curr Drug Targets Immune Endocr Metabol Disord 4:181-5. 2004
    ..Therefore, Akt represents an attractive target for pharmaceutical development for a variety of malignancies, including thyroid cancer...
  7. pmc Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion
    Vasily Vasko
    Department of Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 104:2803-8. 2007
    ..We conclude that EMT is common in PTC invasion and that vimentin regulates thyroid cancer EMT in vitro...
  8. ncbi Akt controls vascular smooth muscle cell proliferation in vitro and in vivo by delaying G1/S exit
    Eugenio Stabile
    Cardiovascular Research Institute, Washington Hospital Center, 110 Irving St NW, 4B 1, Washington, DC 20010, USA
    Circ Res 93:1059-65. 2003
    ....
  9. ncbi Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice
    Andrew J Bauer
    Department of Pediatrics, Walter Reed Army Medical Center, Washington, DC, USA
    Thyroid 12:953-61. 2002
    ..Based on the importance of angiogenesis in solid tumor growth, we hypothesized that angiogenic blockade might reduce the growth of ATC...
  10. ncbi Epidermal growth factor inhibition of c-Myc-mediated apoptosis through Akt and Erk involves Bcl-xL upregulation in mammary epithelial cells
    Danica Ramljak
    Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20057, USA
    Exp Cell Res 287:397-410. 2003
    ..Our findings may be of importance for understanding the emerging role of Bcl-x(L) as a potential marker of poor prognosis in breast cancer...
  11. ncbi 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase
    Leonardo M Porchia
    Division of Endocrinology, Department of Medicine, the Ohio State University Colleges of Medicine and Pharmacy, Columbus, Ohio, USA
    Mol Pharmacol 72:1124-31. 2007
    ..In summary, OSU-03012 is a direct inhibitor of PAK, and inhibition of PAK, either directly or indirectly, may be involved in its biological effects in vitro...
  12. ncbi Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer
    Milena Braga-Basaria
    Washington Hospital Center, MedStar Research Institute, Washington, D C 20010, USA
    J Clin Endocrinol Metab 88:1947-60. 2003
    ..In this review we will discuss the mechanisms of action and preclinical/clinical data for several of these compounds that have the potential to play an important role in the management of thyroid cancer in the future...
  13. ncbi Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202
    Manali Mody
    Department of Biochemistry and Molecular Biology, The George Washington University Medical Center, Washington, District of Columbia 20037, USA
    Endocr Relat Cancer 14:305-15. 2007
    ..We conclude that microarray analysis can determine early TZD-modulated changes in gene expression that help to predict effective in vitro drug combinations...
  14. ncbi Diagnostic molecular markers in thyroid cancer
    Matthew D Ringel
    Department of Medicine, Division of Endocrinology, The Ohio State University, Columbus, Ohio, USA
    Cancer Treat Res 122:295-316. 2004
    ..Additional research in this area is clearly required before a recommendation can be given regarding clinically applicability of these tests...
  15. ncbi Evaluation of adult papillary thyroid carcinomas by comparative genomic hybridization and microsatellite instability analysis
    Andrew J Bauer
    Department of Pediatrics, Walter Reed Army Medical Center, USA, Washington, DC, USA
    Cancer Genet Cytogenet 135:182-6. 2002
    ..026). We conclude that although chromosomal and microsatellite instability are uncommon in PTC, tumors with chromosomal aberrations are more likely to be associated with invasion...
  16. ncbi KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity
    Nikolaos Stathatos
    The Ohio State University, 445D McCampbell Hall, 1581 Dodd Drive, Columbus, Ohio 43210, USA
    J Clin Endocrinol Metab 90:5432-40. 2005
    ..In the present study, our goal was to define the basis of GPR54 action using thyroid cancer cells as a model...
  17. ncbi Phase II study of celecoxib in metastatic differentiated thyroid carcinoma
    Ewa Mrozek
    Division of Hematology, Departments of Internal Medicine, The Ohio State University Thyroid Cancer Unit, The Ohio State University Medical Center, Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio 43210, USA
    J Clin Endocrinol Metab 91:2201-4. 2006
    ..There is increased cyclooxygenase-2 (COX-2) expression in malignant thyroid nodules compared with nonneoplastic and benign thyroid tissue...
  18. ncbi AKT in thyroid tumorigenesis and progression
    Motoo Shinohara
    Divisions of Endocrinology and Oncology, The Ohio State University College of Medicine, 1581 Dodd Drive, Columbus, OH 43210, USA
    Endocrinology 148:942-7. 2007
    ..In this review, the role of AKT in thyroid cancer development and progression are discussed with a focus on areas of current debate in the literature...
  19. ncbi BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 90:6373-9. 2005
    ..Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve risk stratification of this cancer...
  20. ncbi AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma
    Caroline S Kim
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 5128, Bethesda, Maryland 20892 4264, USA
    Endocrinology 146:4456-63. 2005
    ..Thus, TRbeta(PV/PV) mice could be used to further dissect the detailed pathways underlying the progression and metastasis of follicular thyroid carcinoma...
  21. ncbi Akt1 contains a functional leucine-rich nuclear export sequence
    Motoyasu Saji
    The Ohio State University and Arthur G James Comprehensive Cancer Center, Columbus, OH, USA
    Biochem Biophys Res Commun 332:167-73. 2005
    ..Thus, Akt1 contains a functional NES and mutation of the NES results in nuclear-predominant Akt1 activation that is sufficient to induce migration...
  22. ncbi Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination
    Frank Weber
    Clinical Cancer Genetics Program, Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    J Clin Endocrinol Metab 90:2512-21. 2005
    ..Three-gene profiling of thyroid nodules can accurately predict the diagnosis of FTC and FA with high sensitivity and specificity, thus identifying promising targets for further investigation to ultimately improve preoperative diagnosis...
  23. ncbi Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto's autoimmune thyroiditis
    Norikazu Harii
    Edison Biotechnology Institute, Ohio University, Athens, OH 45701, USA
    Mol Endocrinol 19:1231-50. 2005
    ....
  24. ncbi Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma
    Vasily V Vasko
    INSERM U 555, Faculty of Medicine, Mediterranean University, Marseilles, France
    Eur J Endocrinol 151:779-86. 2004
    ....
  25. ncbi Molecular detection of thyroid cancer: differentiating "signal" and "noise" in clinical assays
    Matthew D Ringel
    J Clin Endocrinol Metab 89:29-32. 2004
  26. ncbi Current therapy for childhood thyroid cancer: optimal surgery and the legacy of king pyrrhus
    Matthew D Ringel
    Ann Surg Oncol 10:4-6. 2003
  27. ncbi Paternal imprinting of Galpha(s) in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a
    Emily L Germain-Lee
    Division of Pediatric Endocrinology, Department of Pediatrics, The Johns Hopkins University School of Medicine, Park Building, Suite 211, 600 N Wolfe Street, Baltimore, 21287 2520, MD, USA
    Biochem Biophys Res Commun 296:67-72. 2002
    ..9-40.4%. Expression of NESP55, XLalpha(s), and 1A was uniallelic. We conclude that Galpha(s) is incompletely imprinted in the thyroid, which provides an explanation for mild TSH resistance in PHP type 1a...
  28. pmc Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia
    John E Paes
    Division of Endocrinology, The Ohio State University Medical Center, The Ohio State University, 1581 Dodd Drive, 4th Floor, McCampbell Hall, Columbus, OH 43210, USA
    Endocrinol Metab Clin North Am 37:375-87, viii-ix. 2008
    ..In this article, the role of PI3K pathway activation in thyroid cancer is discussed, with a focus on recent advances...